Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

Author
Barrios, C. H.
Herbst, R. S.
de Marinis, F.
Giaccone, G.
Reinmuth, N.
Vergnenegre, A.
Morise, M.
Felip, E.
Andric, Z.
Geater, S.
Ozguroglu, M.
Mocci, S.
McCleland, M.
Zou, W.
Enquist, I.
Komatsubara, K.
Deng, Y.
Kuriki, H.
Spigel, D. R.
Jassem, J.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/155536
Collections